JGC
FBRX

J. Goldman & Co’s Forte Biosciences FBRX Stock Holding History

J. Goldman & Co’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-107
Closed -$266K – 308
2019
Q2 		$266K Buy
+107
New +$317K 0.02% 242

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

J. Goldman & Co's FBRX Position: Q2 2026 in Review

J. Goldman & Co reduced its Forte Biosciences (FBRX) stake by 15% in Q2 2026, selling an estimated $190K and leaving 46,182 shares worth $981K. The position accounts for 0.03% of the portfolio, ranked #466.

J. Goldman & Co first reported a position in FBRX in Q1 2019 and has held it in 7 quarters since. The position peaked at $1.66M in Q4 2025. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • J. Goldman & Co held 46,182 shares of Forte Biosciences worth $981K as of Q2 2026.
  • J. Goldman & Co sold 7,992 Forte Biosciences shares in Q2 2026, an estimated $190K.
  • Forte Biosciences made up 0.03% of J. Goldman & Co's portfolio in Q2 2026, its #466 holding.
  • J. Goldman & Co first reported a position in Forte Biosciences in Q1 2019 and has held it in 7 quarters since.
  • J. Goldman & Co's Forte Biosciences position peaked at $1.66M in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.